Table 1.
Demographic data and clinical characteristics of all patients included in the study (n = 50)
| Age (years) | 69.4 ± 14.1 (25–90) |
| Men/women | 31/19, 62 vs 38% |
| Body Mass Index (BMI, kg/m2) | 26.1 ± 5.6 (13–44) |
| Dialysis (months) | 65.1 ± 74.0 (5–470) |
| Diabetes (n, %) | 23 (46) |
| Nephrosclerosis (n, %) | 15 (30) |
| Autosomal Dominant Polycystic Disease (n, %) | 4 (8) |
| Chronic glomerulonephritis (n, %) | 8 (16) |
| Vasculitis/anti-GBM-nephropathy (n, %) | 4 (8) |
| Ongoing medication with CNIs (n, %) | 2 (4) |
| Ongoing medication with MMF (n, %) | 1 (2) |
| Previousa treatment with CNI (n, %) | 3 (6) |
| Previousa treatment with Rituximab or Cyclophosphamide (n, %) | 5 (10) |
| Current systemic steroid treatment (n, %) | 7 (14) |
| Previous renal transplant (n, %) | 5 (10) |
Results are expressed as mean ± SD and range (min, max) or as proportions n (%)
CNI, calcineurin inhibitors; MMF, mycophenolate mofetil; GBM, glomerular basement membrane
aWithin the last ten years